AMPH:NASDAQ
Amphastar Pharmaceuticals, Inc
$26.21
arrow_upward
+1.31%(+0.34) 1D
Oct 19, 10:45:27 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMPH...
Open
$25.63
High
$26.31
Low
$25.63
Mkt. cap
1.11B
Avg. vol.
511.19K
Volume
29.71K
P/E ratio
15.33
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.90
Shares outstanding
42.54M
No. of employees
2K
Open
$25.63
High
$26.31
Low
$25.63
Mkt. cap
1.11B
Avg. vol.
511.19K
Volume
29.71K
P/E ratio
15.33
52-wk high
$29.52
52-wk low
$16.64
EPS
$1.71
Beta
0.90
Shares outstanding
42.54M
No. of employees
2K
News stories
From web sources and news partners
BigGo Finance
·
22 minutes ago
S&P 500, Nasdaq Climb at Open as AI Stocks Rebound; Dow Slips
RealMoney Pro
·
16 minutes ago
Charting the Markets: This Chart of the S&P Is Still Bullish. But for How Long?
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
GuruFocus
·
20 minutes ago
Bank of America Securities Upgrades Dow Inc. (DOW) to Neutral on Rising Chemical Prices
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees1.98K
Founded1996
HeadquartersRancho Cucamonga, California, United States
SectorPharmaceutical industry
Websiteamphastar.com